Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Subscribe To Our Newsletter & Stay Updated
